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Identity 
Other names: LIV-1; ZIP6 




SLC39A6 gene contains ten exons. The length of this 
gene is 20864 bases. This gene encodes two transcript 
variants. Isoform 1 utilizes all of ten exons, while 
isoform 2 lacks exon 2 and 10. Consequently, isoform 
2 gives rise to shorter protein than isoform 1. 
Transcription 
Isoform 1; 3637 bases mRNA; 2265 bases of coding 






SLC39A6 encodes the zinc transporter ZIP6. Isoform 1 
consists of 755 amino acids; Isoform 2 consists of 433
amino acids. The molecular weight of ZIP6 is 85 kDa. 
SLC39A6 is a multi-pass membrane protein and 
showing the characteristics of zinc transporter (Taylor 
and Nicholson, 2003). 
Expression 
ZIP6 is highly expressed in normal breast tissue,  
prostate, placenta, kidney, pituitary and corpus 
callosum (Taylor et al., 2003). Elevated expressions in 
malignancy of epithelial origin, such as pancreatic 
cancer are reported (Unno et al., 2009). Its expression 
is also reported in the second heart field progenitors, 
which contribute to the cardiac outflow tract formation 
(Barth et al., 2010). 
Localisation 
Located at cell membrane. 
Function 
According to the structural similarity, may act as a zinc 
influx transporter. Accelerates nuclear translocation of 
the transcriptional factor Snail, the inducer of 
epithelial-mesenchymal transition (EMT), as a 
downstream target of STAT3 pathway in the zebrafish 
gastrula organizer (Yamashita et al., 2004). SLC39A6 
is induced by histone deacetylase inhibitors' treatm nt 
in cancer cells, and involved in the apoptosis induction 
by histone deacetylase inhibitors (Ma et al., 2009). 
Homology 
Mus musculus Slc39a6; Rattus norvegicus Slc39a6; 
Bos Taurus SLC39A6; Pan troglodytes SLC39A6. 
Mutations 
Note 




SLC39A6 is highly expressed in pancreatic cancer cell 
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line and pancreatic cancer tissue. Knockdown of 
SLC39A6 expression in the human pancreatic cancer 
cell line Panc-1 resulted in the reduced tumorigenicity 
in nude mice and acquisition of epithelial phenotype, 




SLC39A6 regulates the expression level of E-cadherin, 
a epithelial marker in human breast cancer cell line 
MCF-7 (Shen et al., 2009). Higher expression of 
SLC39A6 in breast cancer tissue correlates with the 
better outcome of breast cancer patients (Kasper et al., 
2005). 
SLC39A6 is induced upon the treatment of breast 
cancer and cervical cancer cell lines by the histone 
deacetylase inhibitor, TSA. Knockdown of SLC39A6 
resulted in the decreased cell death of TSA-treated 
cancer cells, which indicates the requirement of 




SLC39A6 is involved in the cellular invasion of HeLa 
cells by controlling the ERK-mediated Snail and Slug 
expression (Zhao et al., 2007). 
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